If you're looking to put $10,000 to work in the Australian share market this month, then it could be worth considering the two ASX 200 shares named below.
Both are buy-rated by top brokers and have strong growth potential. Here's what you need to know about them:
The first ASX 200 share to consider investing in is Life360. It is a rapidly expanding global family safety and location services company, known for its popular Life360 app, which had a staggering 76.9 million monthly active users (MAUs) across more than 170 countries as of its last update.
Bell Potter is very positive about Life360's future. The broker sees potential for the company to exceed its FY 2024 guidance and then deliver strong guidance for FY 2025. It states:
Life360 remains a key pick of ours for the following reasons: 1. We expect a strong 2024 result with some chance of a beat to the EBITDA guidance; 2. We anticipate strong 2025 guidance with revenue growth exceeding 20% and positive statutory EBITDA; and 3. We foresee the company being added to the S&P/ASX 100 Index in early March's rebalance.
In addition, Bell Potter believes Life360's strong competitive position and leadership in its niche market provide a solid foundation for long-term growth. The broker explains:
There is some debate about whether inclusion in the large-cap index will be beneficial, but we believe it will be positive. Life360 is a global leader in its category, has a strong competitive moat, is founder-led, and is EBITDA and cash flow positive.
In light of these tailwinds, Bell Potter has a buy rating and $27.75 price target on Life360 shares.
Another ASX 200 share that could be a great option for a $10,000 investment is ResMed. It is a global leader in the treatment of sleep disorders, particularly sleep apnoea, with a market-leading position in CPAP (continuous positive airway pressure) devices.
Goldman Sachs is bullish on ResMed's outlook following a strong second-quarter update. The broker notes that rising awareness of sleep apnoea is translating into higher demand for ResMed's products. It said:
The strength in US device sales (+12% YoY) is early evidence that the growing awareness of Obstructive Sleep Apnea (OSA) from the uptake of consumer wearables and GLP-1 therapies is driving demand for ResMed's products. Importantly, the result reinforced multiple growth levers under ResMed's control.
Goldman Sachs also believes ResMed's shares deserve to trade at a higher multiple given its positive growth trajectory. It explains:
Our Buy recommendation on ResMed is based on (1) continued robust new patient growth for CPAP therapy despite concerns over GLP-1 drugs as an alternative treatment, (2) further market share gains, reinforcing its global leadership position, and (3) expansion of the OSA market beyond the United States. The stock's current valuation does not fully reflect its strong growth outlook.
The broker currently has a buy rating and $49.00 price target on ResMed's shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.